Hard-to-heal wounds: Results of an international survey

Wounds UK

Volumn 7, Issue 4, 2011, Pages 22-32

  White, Richard ^a  

^a UNIVERSITY OF WORCESTER   (United Kingdom)

Author keywords

'Hard to heal' ulcers; Clinician survey; Diabetic foot ulcer; Venous leg ulcer

Indexed keywords

AMELOGENIN; ANTIINFECTIVE AGENT; BECAPLERMIN; PROMOGRAN; UNCLASSIFIED DRUG; WOUND HEALING PROMOTING AGENT;

ARTICLE; CHRONIC WOUND; CLINICAL PRACTICE; DEBRIDEMENT; DIABETIC FOOT; DISEASE DURATION; HEALTH CARE PERSONNEL; HEALTH CARE SURVEY; HUMAN; LEG ULCER; NURSE; PROGNOSIS; SOFT TISSUE INFECTION; SURGICAL TECHNIQUE; TISSUE NECROSIS; TREATMENT RESPONSE; ULCER HEALING; VACUUM ASSISTED CLOSURE; WORK EXPERIENCE; WOUND DRESSING; WOUND FLUID; WOUND HEALING; WOUND INFECTION;

EID: 84856038673     PISSN: 17466814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Acton C (2007) The holistic management of chronic wound pain. Wounds UK 3(1): 61-9
2. Agren MS (1994) Gelatinase activity during wound healing. Br J Dermatol 131(5): 634-40
3. Akbari A, Moodi H, Ghiasi F, Sagheb HM, Rashidi H (2007) Effects of vacuum-compression therapy on healing of diabetic foot ulcers: Randomized controlled trial. J Rehabil Res Dev 44(5): 631-6
4. Allenet B, Parée F, Lebrun T, Carr L, Posnett J, Martini J, Yvon C (2000) Cost-effectiveness modelling of Dermagraft for the treatment of diabetic foot ulcers in the French context. Diabetes Metab 26(2): 125-32 (Pubitemid 30307584)
5. Armstrong DG, Lavery LA (2005) Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 366(9498): 1704-10 (Pubitemid 41587449)
6. Barwell JR, Davies CE, Deacon J, et al (2004) Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet 363(9424): 1854-9 (Pubitemid 38748640)
7. Benbow SJ, Wallymahmed ME, MacFarlane IA (1998) Diabetic peripheral neuropathy and quality of life. QJM 91(11): 733-7 (Pubitemid 28508618)
8. Best Practice Statement (2011) The use of topical antiseptic/ antimicrobial agents in wound management. 2nd edn. Wounds UK, London
9. Bishop SM, Walker M, Rogers AA, Chen WY (2003) Importance of moisture balance at the wound-dressing interface. J Wound Care 12(4): 125-8
10. Blume PA, Walters J, Payne W, Ayala Y, Lantis M (2008) Comparison of negative pressure wound therapy utilizing vacuum-assisted closure to advanced moist wound therapy in the treatment of diabetic foot ulcers - a multicenter randomized controlled trial. Diabetes Care 31(4): 631-6
11. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, et al (2005) The global burden of diabetic foot disease. Lancet 366(9498): 1719-24 (Pubitemid 41587452)
12. Boyd G, Butcher M, Glover D, Kingsley A (2004) Prevention of non-healing wounds through the prediction of chronicity. J Wound Care 13(7): 265-6
13. Cardinal M (2008) Early healing rates and wound area measurements are reliable predictors of later complete wound closure. Wound Rep Regen 16(1): 19-22
14. Charles CA, Tomic-Canic M, Vincek V, et al (2008) A gene signature of nonhealing venous ulcers: potential diagnostic markers. J Am Acad Dermatol 59(5): 758-71
15. Cutting K, Harding K (1994) Criteria for identifying wound infection. J Wound Care 3(4): 198-201
16. Cutting KF, White RJ (2005) Criteria for identifying wound infection. Ostomy Wound Management 51(1): 6-13
17. Dang CN, Prasad YD, Boulton AJ, Jude EB (2003) Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 20(2): 159-61 (Pubitemid 36269659)
18. Edmonds M, Boulton A, Buckenham T et al (1996) Report of the Diabetic Foot and Amputation Group. Diabet Med 13(9 Suppl 4): S27-42 (Pubitemid 26312832)
19. Eginton MT, Brown KR, et al (2003) A prospective randomized evaluation of negative-pressure wound dressings for diabetic foot wounds. Ann Vasc Surg 17(6): 645-9 (Pubitemid 37553487)
20. Enoch S, Price P (2004) Should alternative endpoints be considered to evaluate outcomes in chronic recalcitrant wounds? World Wide Wounds. Available online at: www.worldwidewounds.com/2004/october/Enoch-Part2/Alternative- Endpoints-To-Healing.html [accessed 25 February 2011]
21. Enoch S, Harding K (2003) Wound Bed Preparation: the science behind the removal of barriers to healing [PART 1]. Wounds 15(7): 213-29 (Pubitemid 36928402)
22. European Wound Management Association (2008) Hard to heal wounds: a holistic approach. MEP Ltd, London
23. Flanagan M (2003) Wound measurement: can it help us to monitor progression to healing? J Wound Care 12(5): 189-94
24. Ghatnekar O, Willis M, Persson U (2002) Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. J Wound Care 11(2): 70-4
25. Ghatnekar O, Persson U, Willis M, et al (2001) Cost-effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 19(7): 767-78 (Pubitemid 32664733)
26. Gohel MS, Taylor M, Earnshaw JJ, et al (2005) Risk factors for delayed healing and recurrence of chronic venous leg ulcers - an analysis of 1324 legs. Eur J Vasc Endovasc Surg 29(1): 74-7 (Pubitemid 39618995)
27. Gohel MS, Windhaber RA, Tarlton JF, et al (2008) The relationship between cytokine concentrations and wound healing in chronic venous ulceration. J Vasc Surg 48(5): 1272-7
28. Harding KG, Morris HL, Patel GK (2006) Science, medicine and the future: healing chronic wounds. Br Med J 324(7345): 160-3
29. Huldt-Nystrom T, Meuleneire F, Acton C (2008) Xelma®, an advanced wound treatment for venous ulcers: a European perspective. Wounds UK 4(1): 1-5
30. Jeffcoate WJ, Harding KG (2003) Diabetic foot ulcers. Lancet 361(9368): 1545-51 (Pubitemid 36566350)
31. Jude E, Schaper N (2007) Treating painful diabetic polyneuropathy. Br Med J 335(7610): 57-8 (Pubitemid 47123273)
32. Kingsley A (2001) A proactive approach to wound infection. Nurs Standard 15(30): 50-8
33. Korstanje MJ (1995) Venous stasis ulcers. Diagnostic and surgical considerations. Dermatol Surg 21(7): 635-40
34. Leese G (2007) Scottish foot ulcer risk score predicts foot ulcer healing in a regional specialist foot clinic. Diabetes Care 30(8): 2064-9
35. Margolis DJ (2000) Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. Arch Dermatol 136(12): 1531-5
36. Margolis DJ (2004) The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Rep Regen 12(2): 163-8
37. Margolis DJ, Allen-Taylor L, Hoffstad O, et al (2005) Diabetic neuropathic foot ulcers and amputation. Wound Rep Regen 13(3): 230-6 (Pubitemid 40848014)
38. Margolis DJ, Kantor J, Berlin JA (1999) Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 22(5): 692-5 (Pubitemid 29220765)
39. Meaume S, Couilliet D, Vin F (2005) Prognostic factors for venous ulcer healing in a non-selected population of ambulatory patients. J Wound Care 14(1): 31-4
40. McCallon SK, Knight CA, ValiulusJP, et al (2000) Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. Ostomy Wound Manage 46(8): 28-34
41. Moore K (2003) Compromised wound healing: a scientific approach to treatment. Br J Community Nurs 8(6): 274-8
42. Moore K, Huddleston E, Stacey MC, Harding KG (2007) Venous leg ulcers - the search for a prognostic indicator. Int Wound J 4(2): 163-72
43. Nelson E, Cullum N, Jones J (2006). Venous leg ulcers. Clin Evidence (15): 2607-26
44. Phillips TJ, Machado F, Trout R, et al (2000) Prognostic indicators in venous ulcers. J Am Acad Dermatol 43(4): 627-30
45. Persson U, Willis M, Odergaard K, Apelqvist J (2000) The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): A core model with an application using Swedish cost data. Value In Health 3(S1): S39-S46 (Pubitemid 32066643)
46. Piaggesi A, Schipani E, Campi F, et al (1998) Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med 15(5): 412-7 (Pubitemid 28197110)
47. Rathur HM, Boulton AJ (2007) The diabetic foot. Clin Dermatol 25(1): 109-20 (Pubitemid 46177468)
48. Rayment EA, Upton Z (2009) Review: finding the culprit: a review of the influence of proteases on the chronic wound environment. Int J Low Extrem Wounds 8(1): 19-27
49. Redekop WK, McDonnell J, Verboom P, et al (2003) The cost-effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics 21(16): 1171-83 (Pubitemid 37463826)
50. Redekop WK, Stolk EA, Kok E, et al (2004) Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 30(6): 549-56 (Pubitemid 40070357)
51. Reichenberg J, Davis M (2005) Venous ulcers. Semin Cutan Med Surg 24(4): 216-26 (Pubitemid 43011389)
52. Rippon M, Davies P, White R, Bosanquet N (2007) The economic impact of hard-to-heal leg ulcers. Wounds UK 3(2): 58-69 (Pubitemid 47195132)
53. Romanelli M, Dini V, Vowden P, Agren MS (2008a) Effect of amelogenin extracellular matrix protein and compression on hard-to-heal venous leg ulcers: follow-up data. J Wound Care 17(1): 17-23
54. Romanelli M, Dini V, Vowden P, Agren M (2008b) Amelogenin, an extracellular matrix protein, in the treatment of venous leg ulcers and other hard-to-heal wounds: experimental and clinical evidence. Clin Interv Aging 3(2): 263-72 (Pubitemid 352037866)
55. Sheehan P, Jones P, Caselli A, et al (2003) Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 26(6): 1879-82 (Pubitemid 36929137)
56. Silhi N (1998) Diabetes and wound healing. J Wound Care 7(1): 47-51
57. Smiell JM, Jeffery Wieman TJ, Steed DL, et al (1999) Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Rep Regen 7(5): 335-46 (Pubitemid 29523009)
58. Steed DL (1995) Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 21(1): 71-8; 79-81
59. Soon K, Acton C (2006) Pain-induced stress: a barrier to wound healing. Wounds UK 2(4): 92-101 (Pubitemid 44902511)
60. Steed DL (2006) Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 117(7 Suppl): 143S-151S.
61. Veves A, Sheehan P, Pham HT (2002) A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 137(7): 822-7 (Pubitemid 34743174)
62. Vin F, Teot L, Meaume S (2002) The healing properties of Promogran in venous leg ulcers. J Wound Care 11(9): 335-41
63. Vowden P, Apelqvist J, Moffatt C (2008) Wound complexity and healing In: Hard to heal wounds: a holistic approach. MEP Ltd, London: 2-9
64. Vowden P, Romanelli M, Peter R, et al (2006) The effect of amelogenins (Xelma) on hard-to-heal venous leg ulcers. Wound Rep Regen 14(3): 240-6 (Pubitemid 43979252)
65. Vowden P, Romanelli M, Price P (2007) Effect of amelogenin extracellular matrix protein and compression on hard-to-heal venous leg ulcers. J Wound Care 16(5): 189-95
66. White R (2008a) A multinational survey of the assessment of pain when removing dressings. Wounds UK 4(1): 58-69
67. White R (2008b) Delayed wound healing: in whom, what, when and why? Primary Health Care 18(2): 40-6
68. White R J (2010) Delayed wound healing: Who, when, why, and in whom? Nurs Standard Autumn Suppl 1(1): 24-32
69. Wolcott RD, Kennedy JP, Dowd SE (2009) Regular debridement is the main tool for maintaining a healthy wound bed in most chronic wounds. J Wound Care 18(2): 54-6
70. Zimny S, Schatz H, Pfohl M (2002) Determinants and estimation of healing times in diabetic foot ulcers. J Diabetes Complications 16(5): 327-32